SEC Form 4 · accession 0001209191-18-004680

ACORDA THERAPEUTICS INC · ACOR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief, Bus. Ops & PAO

Period of report

Jan 18, 2018

Accepted (ET)

Jan 22, 2018 · 8:41 am EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001008848

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Jan 18, 2018	M	582	$19.81	A	5,275	D
Common Stock^F1	Jan 18, 2018	S	582	$27.00	D	4,693	D
Common Stock^F1	Jan 19, 2018	M	30,418	$19.81	A	35,111	D
Common Stock^F1,F2	Jan 19, 2018	S	29,918	$27.5756	D	5,193	D
Common Stock^F1,F3	Jan 19, 2018	S	500	$28.38	D	4,693	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F1,F4	$19.81	Jan 18, 2018	M	582	D	—	Mar 5, 2018	Common Stock	582	30,418	D
Employee Stock Option (right to buy)^F1,F4	$19.81	Jan 19, 2018	M	30,418	D	—	Mar 5, 2018	Common Stock	30,418	0	D

F1Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised.
F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $27.05 to $27.80 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $28.05 to $28.60 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4The shares subject to these options vested in installments and were fully vested on 1/01/2012.